CompletedNot Applicable

Comparison of the Efficacy of Extracorporeal Shock Wave Therapy and Suprascapular Nerve Block in Hemiplegic Shoulder Pain

Turkey (Türkiye)67 participantsStarted 2023-04-01

Plain-language summary

This study aimed to compare the effectiveness of extracorporeal shock wave therapy (ESWT) and suprascapular nerve block (SSNB) with conventional treatment for hemiplegic shoulder pain. A total of 67 patients aged 45-70 years, treated at the Department of Physical Therapy and Rehabilitation at Başakşehir Çam and Sakura City Hospital between April 1, 2023, and January 1, 2024, were randomly assigned to three groups. The first group (n=24) received conventional treatment, the second group (n=22) received conventional treatment plus one session of ultrasound-guided suprascapular nerve block, and the third group (n=21) received conventional treatment plus ESWT applied for 2 weeks, 4 days per week at 12 Hz and 2-3 bars. All groups were evaluated clinically and ultrasonographically before treatment, at 1 month, and at 3 months. Pain intensity was assessed using the visual analog scale, upper extremity motor function with the Fugl-Meyer Motor Scale, and supraspinatus muscle tear size via ultrasound.

Who can participate

Age range45 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with hemorrhagic or ischemic stroke at least 3 months prior to enrollment. Patients with shoulder pain of at least 5 cm on the 10-cm Visual Analog Scale (VAS) following hemiplegia. Patients aged 45-70 years. Patients with partial tear of the supraspinatus muscle/tendon confirmed by ultrasonographic evaluation. Exclusion Criteria: * Patients with limited cooperation. Patients who received local anesthetic or corticosteroid injection to the shoulder region within the last 3 months. Patients with a history of surgery or radiotherapy in the shoulder region. Patients with pre-existing shoulder pain prior to the diagnosis of stroke. Patients with a cardiac pacemaker. Patients with malignancy or signs of acute inflammation in the treatment area. Patients with coagulation disorders or an INR ≥ 4. Patients with vascular conditions such as deep vein thrombosis, phlebitis, varicose veins, or arterial disease.

What they're measuring

Visual Analog Scale

Timeframe: Baseline, 1 month, and 3 months after treatment initiation.

Trial details

NCT IDNCT07485192

SponsorKars State Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-01-01